Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2012, Article ID 343491, 4 pages
http://dx.doi.org/10.1155/2012/343491
Case Report

Salvage Therapy for Refractory Aids-Related Primary Central Nervous System Lymphoma

Department of Internal Medicine, Clínica y Maternidad Suizo, Argentina, Avenida Pueyrredon 1461, C1118AAE Buenos Aires, Argentina

Received 28 July 2012; Accepted 26 August 2012

Academic Editors: K. Aogi, J. I. Mayordomo, and G. P. Vandoros

Copyright © 2012 Hugo Ferro and Eduardo Parino. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Reni, A. J. M. Ferreri, and E. Villa, “Second-line treatment for primary central nervous system lymphoma,” British Journal of Cancer, vol. 79, no. 3-4, pp. 530–534, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. A. J. M. Ferreri, S. Dell'Oro, M. Foppoli et al., “MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas,” Neurology, vol. 66, no. 9, pp. 1435–1438, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. P. M. P. Poortmans, H. C. Kluin-Nelemans, H. Haaxma-Reiche et al., “High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962,” Journal of Clinical Oncology, vol. 21, no. 24, pp. 4483–4488, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. I. T. Gavrilovic, A. Hormigo, J. Yahalom, L. M. DeAngelis, and L. E. Abrey, “Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma,” Journal of Clinical Oncology, vol. 24, no. 28, pp. 4570–4574, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. P. L. Nguyen, A. Chakravarti, D. M. Finkelstein, F. H. Hochberg, T. T. Batchelor, and J. S. Loeffler, “Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma,” Journal of Clinical Oncology, vol. 23, no. 7, pp. 1507–1513, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. A. F. Hottinger, L. M. Deangelis, J. Yahalom, and L. E. Abrey, “Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma,” Neurology, vol. 69, no. 11, pp. 1178–1182, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. A. M. Omuro and L. E. Abrey, “Chemotherapy for primary central nervous system lymphoma,” Neurosurgical Focus, vol. 21, no. 5, article E12, 2006. View at Google Scholar · View at Scopus
  8. R. H. Enting, A. Demopoulos, L. M. DeAngelis, and L. E. Abrey, “Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide,” Neurology, vol. 63, no. 5, pp. 901–903, 2004. View at Google Scholar · View at Scopus
  9. E. T. Wong, R. Tishler, L. Barron, and J. K. Wu, “Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas,” Cancer, vol. 101, no. 1, pp. 139–145, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. E. T. Wong, L. Barron, J. Bloom, and J. Wu, “Durable responses from immunochemotherapy with rituximab and temozolomide in patients with CNS lymphomas,” Cancer Biother Radiopharm, vol. 19, article 514, 2004. View at Google Scholar
  11. M. Santisteban, Y. Nieto, S. De la Cruz, J. Aristu, J. L. Zubieta, and O. Fernández Hidalgo, “Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule,” Clinical and Translational Oncology, vol. 9, no. 7, pp. 465–467, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Alas and B. Bonavida, “Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs,” Cancer Research, vol. 61, no. 13, pp. 5137–5144, 2001. View at Google Scholar · View at Scopus
  13. C. Hoffmann, S. Tabrizian, E. Wolf et al., “Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery,” AIDS, vol. 15, no. 16, pp. 2119–2127, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. D. J. Skiest and C. Crosby, “Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma,” AIDS, vol. 17, no. 12, pp. 1787–1793, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Wyen, B. Jensen, M. Hentrich et al., “Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients,” AIDS, vol. 26, no. 4, pp. 457–464, 2012. View at Publisher · View at Google Scholar · View at Scopus